Geode Capital Management
TVRD

Geode Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Geode Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$580K Buy
182,339
+25,206
+16% +$98.8K ﹤0.01% 3532
2025
Q4 		$676K Buy
157,133
+9,214
+6% +$82.6K ﹤0.01% 3494
2025
Q3 		$5.77M Buy
147,919
+35,781
+32% +$1.02M ﹤0.01% 2707
2025
Q2 		$2.62M Buy
112,138
+99,016
+755% +$2.34M ﹤0.01% 3050
2025
Q1 		$200K Buy
13,122
+561
+4% +$8.47K ﹤0.01% 3850
2024
Q4 		$231K Sell
12,561
-1
-0% -$11 ﹤0.01% 3861
2024
Q3 		$139K Sell
12,562
-568
-4% -$6.66K ﹤0.01% 4012
2024
Q2 		$122K Sell
13,130
-15,248
-54% -$364K ﹤0.01% 4081
2024
Q1 		$930K Buy
28,378
+351
+1% +$9.1K ﹤0.01% 3390
2023
Q4 		$750K Buy
28,027
+1,003
+4% +$41.5K ﹤0.01% 3459
2023
Q3 		$1.63M Buy
27,024
+1,071
+4% +$100K ﹤0.01% 3142
2023
Q2 		$2.64M Buy
25,953
+1,166
+5% +$161K ﹤0.01% 3025
2023
Q1 		$4.38M Buy
24,787
+972
+4% +$326K ﹤0.01% 2691
2022
Q4 		$9.21M Buy
23,815
+1,032
+5% +$392K ﹤0.01% 2320
2022
Q3 		$7.68M Buy
22,783
+54
+0.2% +$19.6K ﹤0.01% 2431
2022
Q2 		$7.47M Buy
22,729
+378
+2% +$133K ﹤0.01% 2454
2022
Q1 		$9.78M Sell
22,351
-1,011
-4% -$415K ﹤0.01% 2358
2021
Q4 		$10.2M Buy
23,362
+108
+0.5% +$54.3K ﹤0.01% 2431
2021
Q3 		$12.9M Buy
23,254
+1,242
+6% +$623K ﹤0.01% 2273
2021
Q2 		$11.3M Buy
22,012
+1,958
+10% +$1.24M ﹤0.01% 2375
2021
Q1 		$15.7M Buy
20,054
+1,279
+7% +$876K ﹤0.01% 2032
2020
Q4 		$10.2M Buy
18,775
+860
+5% +$451K ﹤0.01% 2171
2020
Q3 		$8.21M Buy
17,915
+366
+2% +$213K ﹤0.01% 2074
2020
Q2 		$10.8M Buy
17,549
+649
+4% +$358K ﹤0.01% 1891
2020
Q1 		$8.04M Buy
16,900
+1,887
+13% +$1.03M ﹤0.01% 1871
2019
Q4 		$8.71M Buy
15,013
+422
+3% +$296K ﹤0.01% 2109
2019
Q3 		$9.6M Buy
14,591
+2,192
+18% +$1.82M ﹤0.01% 1968
2019
Q2 		$9.6M Buy
12,399
+1,345
+12% +$945K ﹤0.01% 1988
2019
Q1 		$7.81M Buy
11,054
+823
+8% +$493K ﹤0.01% 2058
2018
Q4 		$4.79M Buy
10,231
+574
+6% +$370K ﹤0.01% 2250
2018
Q3 		$8.33M Buy
9,657
+2,714
+39% +$1.96M ﹤0.01% 2050
2018
Q2 		$4.79M Buy
6,943
+580
+9% +$295K ﹤0.01% 2351
2018
Q1 		$2.83M Buy
6,363
+91
+1% +$44.1K ﹤0.01% 2575
2017
Q4 		$2.76M Buy
6,272
+93
+2% +$42.4K ﹤0.01% 2575
2017
Q3 		$3.04M Buy
6,179
+102
+2% +$51.1K ﹤0.01% 2496
2017
Q2 		$3.37M Buy
6,077
+907
+18% +$576K ﹤0.01% 2423
2017
Q1 		$3.42M Buy
5,170
+245
+5% +$131K ﹤0.01% 2343
2016
Q4 		$1.65M Buy
4,925
+1,166
+31% +$374K ﹤0.01% 2737
2016
Q3 		$1.13M Buy
3,759
+448
+14% +$97.1K ﹤0.01% 2875
2016
Q2 		$573K Buy
3,311
+87
+3% +$18.9K ﹤0.01% 3168
2016
Q1 		$721 Buy
3,224
+59
+2% +$17.6K ﹤0.01% 3049
2015
Q4 		$1.92M Buy
3,165
+46
+1% +$25.3K ﹤0.01% 2512
2015
Q3 		$1.6M Buy
3,119
+1,396
+81% +$934K ﹤0.01% 2580
2015
Q2 		$753K Buy
1,723
+247
+17% +$95.5K ﹤0.01% 3035
2015
Q1 		$533K Buy
1,476
+161
+12% +$60.9K ﹤0.01% 3170
2014
Q4 		$471K Buy
1,315
+74
+6% +$23.8K ﹤0.01% 3219
2014
Q3 		$374K Buy
1,241
+392
+46% +$161K ﹤0.01% 3291
2014
Q2 		$520K Buy
849
+11
+1% +$5.92K ﹤0.01% 3150
2014
Q1 		$561K Buy
+838
New +$496K ﹤0.01% 3102

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's TVRD Position: Q1 2026 in Review

Geode Capital Management increased its Tvardi Therapeutics (TVRD) stake by 16% in Q1 2026, buying an estimated $98.8K and bringing the position to 182,339 shares worth $580K. The position accounts for ﹤0.01% of the portfolio, ranked #3532.

Geode Capital Management first reported a position in TVRD in Q1 2014 and has held it in 49 quarters since. The position peaked at $15.7M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Geode Capital Management held 182,339 shares of Tvardi Therapeutics worth $580K as of Q1 2026.
  • Geode Capital Management bought 25,206 Tvardi Therapeutics shares in Q1 2026, an estimated $98.8K.
  • Tvardi Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3532 holding.
  • Geode Capital Management first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Geode Capital Management's Tvardi Therapeutics position peaked at $15.7M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.